From somatic variants towards precision oncology

• Verfasst von: Perera-Bel, Júlia [VerfasserIn]
• Verfasst von: Hutter, Barbara [VerfasserIn]
• Verfasst von: Heining, Christoph [VerfasserIn]
• Verfasst von: Fröhlich, Martina [VerfasserIn]
• Verfasst von: Fröhling, Stefan [VerfasserIn]
• Verfasst von: Glimm, Hanno [VerfasserIn]
• Verfasst von: Brors, Benedikt [VerfasserIn]
• Titel: From somatic variants towards precision oncology
• Titelzusatz: evidence-driven reporting of treatment options in molecular tumor boards
• Verf.angabe: Júlia Perera-Bel, Barbara Hutter, Christoph Heining, Annalen Bleckmann, Martina Fröhlich, Stefan Fröhling, Hanno Glimm, Benedikt Brors and Tim Beißbarth
• E-Jahr: 2018
• Jahr: 15 March 2018
• Umfang: 15 S.
• Fussnoten: Gesehen am 21.04.2020
• Titel Quelle: Enthalten in: Genome medicine
• Ort Quelle: London : BioMed Central, 2009
• Jahr Quelle: 2018
• Band/Heft Quelle: 10(2018) Artikel-Nummer 18, 15 Seiten
• ISSN Quelle: 1756-994X
• DOI: doi:10.1186/s13073-018-0529-2
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1695259599

Abstract

A comprehensive understanding of cancer has been furthered with technological improvements and decreasing costs of next-generation sequencing (NGS). However, the complexity of interpreting genomic data is hindering the implementation of high-throughput technologies in the clinical context: increasing evidence on gene-drug interactions complicates the task of assigning clinical significance to genomic variants. Here we present a method that automatically matches patient-specific genomic alterations to treatment options. The method relies entirely on public knowledge of somatic variants with predictive evidence on drug response. The output report is aimed at supporting clinicians in the task of finding the clinical meaning of genomic variants. We applied the method to 1) The Cancer Genome Atlas (TCGA) and Genomics Evidence Neoplasia Information Exchange (GENIE) cohorts and 2) 11 patients from the NCT MASTER trial whose treatment discussions included information on their genomic profiles. Our reporting strategy showed a substantial number of patients with actionable variants in the analyses of TCGA and GENIE samples. Notably, it was able to reproduce experts’ treatment suggestions in a retrospective study of 11 patients from the NCT MASTER trial. Our results establish a proof of concept for comprehensive, evidence-based reports as a supporting tool for discussing treatment options in tumor boards. We believe that a standardized method to report actionable somatic variants will smooth the incorporation of NGS in the clinical context. We anticipate that tools like the one we present here will become essential in summarizing for clinicians the growing evidence in the field of precision medicine. The R code of the presented method is provided in Additional file 6 and available at https://github.com/jperera-bel/MTB-Report .